Orforglipron for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 15 registered trials.

Why this status

  1. 3 Apr 2023: Trial started, NCT05803421
  2. 7 Apr 2023: Trial registered, NCT05803421
  3. 24 May 2023: Trial registered, NCT05872620
  4. 5 Jun 2023: Trial started, NCT05872620
  5. 2 Aug 2023: Trial registered, NCT05971940
  6. 9 Aug 2023: Trial started, NCT05971940
  7. 24 Aug 2023: Trial registered, NCT06010004
  8. 21 Sep 2023: Trial registered, NCT06045221
  9. 22 Sep 2023: Trial started, NCT06045221
  10. 28 Sep 2023: Trial started, NCT06010004
  11. 31 Oct 2023: Trial registered, NCT06109311
  12. 10 Nov 2023: Trial started, NCT06109311
  13. 5 Jan 2024: Trial registered, NCT06192108
  14. 10 Jan 2024: Trial started, NCT06192108
  15. 15 May 2025: Trial registered, NCT06972472
  16. 15 May 2025: Trial started, NCT06993792
  17. 19 May 2025: Trial started, NCT06972472
  18. 29 May 2025: Trial registered, NCT06993792
  19. 29 May 2026: Trial registered, NCT07613307
  20. 25 Jun 2026: Trial registered, NCT07668336
  21. 8 Jul 2026: Trial started, NCT07668336
  22. 15 Jul 2026: Trial started, NCT07613307

The trials

NCT04426474: A Study of LY3502970 in Participants With Type 2 Diabetes

State
Completed
Phase
Phase 1
People
68 taking part
Started
8 Oct 2020
Primary completion
12 Jul 2021
Arms
LY3502970
Results
Posted on the registry
  1. 11 Jun 2020: Trial registered
  2. 8 Oct 2020: Trial started
  3. 12 Jul 2021: Trial completed
  4. 26 May 2026: Trial results posted

NCT05048719: A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 2
People
383 taking part
Started
15 Sep 2021
Primary completion
30 Sep 2022
Arms
3 milligrams (mg) LY3502970, 12 mg LY3502970, 24 mg LY3502970, 36 mg LY3502970 - 1, 36 mg LY3502970 - 2, 45 mg LY3502970 - 1, 45 mg LY3502970 - 2
Results
Posted on the registry
  1. 15 Sep 2021: Trial started
  2. 17 Sep 2021: Trial registered
  3. 30 Sep 2022: Trial completed
  4. 17 Oct 2023: Trial results posted

NCT05086445: A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 1
People
62 taking part
Started
12 Nov 2021
Primary completion
5 Sep 2022
Arms
LY3502970 (Part A), LY3502970 (Part B)
Results
Posted on the registry
  1. 21 Oct 2021: Trial registered
  2. 12 Nov 2021: Trial started
  3. 5 Sep 2022: Trial completed
  4. 16 Jul 2026: Trial results posted

NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

State
Completed
Phase
Phase 3
People
2,749 taking part
Started
3 Apr 2023
Primary completion
16 Mar 2026
Arms
Orforglipron
Results
None posted
  1. 3 Apr 2023: Trial started
  2. 7 Apr 2023: Trial registered
  3. 16 Mar 2026: Trial completed

NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

State
Completed
Phase
Phase 3
People
1,613 taking part
Started
5 Jun 2023
Primary completion
8 Aug 2025
Arms
6 mg Orforglipron QD, 12 mg Orforglipron QD, 36 mg Orforglipron QD
Results
Posted on the registry
  1. 24 May 2023: Trial registered
  2. 5 Jun 2023: Trial started
  3. 8 Aug 2025: Trial completed
  4. 4 Sep 2026: Trial results posted

NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

State
Completed
Phase
Phase 3
People
559 taking part
Started
9 Aug 2023
Primary completion
3 Apr 2025
Arms
3 mg Orforglipron, 12 mg Orforglipron, 36 mg Orforglipron
Results
Posted on the registry
  1. 2 Aug 2023: Trial registered
  2. 9 Aug 2023: Trial started
  3. 3 Apr 2025: Trial completed
  4. 22 Apr 2026: Trial results posted

NCT06010004: A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

State
Completed
Phase
Phase 3
People
401 taking part
Started
28 Sep 2023
Primary completion
5 Jun 2025
Arms
3 mg Orforglipron, 12 mg Orforglipron, 36 mg Orforglipron
Results
Posted on the registry
  1. 24 Aug 2023: Trial registered
  2. 28 Sep 2023: Trial started
  3. 5 Jun 2025: Trial completed
  4. 30 Jun 2026: Trial results posted

NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

State
Completed
Phase
Phase 3
People
1,698 taking part
Started
22 Sep 2023
Primary completion
22 Aug 2025
Arms
12 mg Orforglipron, 36 mg Orforglipron
Results
Posted on the registry
  1. 21 Sep 2023: Trial registered
  2. 22 Sep 2023: Trial started
  3. 22 Aug 2025: Trial completed
  4. 15 Sep 2026: Trial results posted

NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

State
Completed
Phase
Phase 3
People
546 taking part
Started
10 Nov 2023
Primary completion
15 Sep 2025
Arms
3 mg Orforglipron QD, 12 mg Orforglipron QD, 36 mg Orforglipron QD
Results
Posted on the registry
  1. 31 Oct 2023: Trial registered
  2. 10 Nov 2023: Trial started
  3. 15 Sep 2025: Trial completed
  4. 1 Oct 2026: Trial results posted

NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

State
Completed
Phase
Phase 3
People
962 taking part
Started
10 Jan 2024
Primary completion
26 Sep 2025
Arms
Orforglipron 3 mg, Orforglipron 12 mg, Orforglipron 36 mg
Results
Posted on the registry
  1. 5 Jan 2024: Trial registered
  2. 10 Jan 2024: Trial started
  3. 26 Sep 2025: Trial completed
  4. 16 Oct 2026: Trial results posted

NCT06972472: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

State
Under way
Phase
Phase 3
People
600 planned
Started
19 May 2025
Primary completion
Aug 2027
Arms
Orforglipron Dose 1, Orforglipron Dose 2, Orforglipron Dose 3, Orforglipron Dose 4
Results
None posted
  1. 15 May 2025: Trial registered
  2. 19 May 2025: Trial started

NCT06993792: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,400 planned
Started
15 May 2025
Primary completion
Aug 2027
Arms
Orforglipron Dose 1 (Study GZP1), Orforglipron Dose 2 (Study GZP1), Orforglipron Dose 3 (Study GZP1), Orforglipron Dose 4 (Study GZP1), Orforglipron Dose 1 (Study GZP2), Orforglipron Dose 2 (Study GZP2), Orforglipron Dose 3 (Study GZP2), Orforglipron Dose 4 (Study GZP2)
Results
None posted
  1. 15 May 2025: Trial started
  2. 29 May 2025: Trial registered

NCT07613307: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

State
Under way
Phase
Phase 3
People
130 planned
Started
15 Jul 2026
Primary completion
May 2027
Arms
Orforglipron
Results
None posted
  1. 29 May 2026: Trial registered
  2. 15 Jul 2026: Trial started

NCT07668336: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

State
Under way
Phase
Phase 3
People
170 planned
Started
8 Jul 2026
Primary completion
Mar 2030
Arms
Orforglipron
Results
None posted
  1. 25 Jun 2026: Trial registered
  2. 8 Jul 2026: Trial started

NCT07739537: PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

State
Not started
Phase
Phase 4
People
100 planned
Started
1 Oct 2026
Primary completion
30 Sep 2029
Arms
Drug challenge
Results
None posted
  1. 31 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.